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A B S T R A C T
Human induced pluripotent stem cells (hiPSCs) from individual patient basis are considered a powerful resource to model human diseases. However, to study
complex multigenic diseases such as Congenital Heart Disease, it is crucial to generate perfect isogenic controls to understand gene singularity and contribution.
Here, we report the engendering of an isogenic hiPSC line with homozygous correction of c.455G > A alteration in the DAND5 gene, using CRISPR/Cas9 technology.
The characterization of a clone of this cell line demonstrates normal karyotype, pluripotent state, and potential to diﬀerentiate in vitro towards endoderm, mesoderm,
and ectoderm.
Resource Table:
Unique stem cell lines i-
dentiﬁer
NMSUNLi003
Alternative names of st-
em cell lines
iUC-DAND5_455/10C
Institution CEDOC, NOVA Medical School
Contact information of
distributor
José A. Belo,
jose.belo@nms.unl.pt
Type of cell lines iPSC
Origin Human
Cell Source Exfoliated renal epithelial cells isolated from urine
Clonality Clonal
Method of reprogram-
ming
Sendai virus
Multiline rationale Isogenic cell line
Gene modiﬁcation Yes
Type of modiﬁcation Gene correction
Associated disease Heterotaxy and Congenital Heart Disease
Gene/locus Rs45513495:DAND5, c.455; p.R152
Method of modiﬁcation CRISPR
Name of transgene or r-
esistance
No transgene
Inducible/constitutive s-
ystem
N/A
Date archived/stock da-
te
July 2019
Cell line repository/ba-
nk
N/A
Ethical approval Approved by the Ethics Committee of NOVA Medical
School (Protocol no. 13/2016/CEFCM) and by the
National Committee for Data Protection (CNPD, Permit
Nº8694/2016)
1. Resource utility
The molecular mechanism by which alterations on DAND5 gene
increase the risk of the complex multigenic Congenital Heart Disease is
still undetermined. The generated corrected iUC-DAND5_455/10C line
is the most ultimate control to establish models in order to understand
the role of this gene in patients with DAND5 c.455 G > A variant, in
terms of the molecular mechanisms of cardiomyocyte proliferation,
drug screening, and regenerative medicine.
2. Resource details
DAND5 is a secreted molecule that controls the bioavailability of
NODAL signaling at the organizer during early embryogenesis
(Inacio et al., 2013). The exact localization and temporal expression of
NODAL are what determines the correct establishment of the anatomic
asymmetries on the visceral organs, in particular, the anatomical de-
velopment of the heart (Araujo et al., 2014; Belo et al., 2017). The
c.455G > A variant in the functional domain of DAND5 gene causes a
signiﬁcative decrease in the activity of this NODAL antagonist (Cristo
et al.,2017a). This non-synonymous variant was ﬁrst identiﬁed in a
patient clinically diagnosed with a ventricular septal defect with
overriding aorta, right ventricular hypertrophy, and pulmonary atresia,
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Fig. 1. Characterization of iUC-DAND5_455/10C cell line. A. Gene correction strategy. B. DNA sequence showing the c.455G > A variant in the iUC-DAND5_455/10
line and the same region of the corrected iUC-DAND5_455/10C cell line. C. Bright-ﬁeld image of the iUC-DAND5_455/10C iPSC line morphology. D. Karyotype of a
representative metaphase showing normal 46 chromosomes (XY). F. Real-Time PCR analysis of the endogenous pluripotency markers. E. Immunodetection of
pluripotency markers of iUC-DAND5_455/10C cell line. G. Immunoﬂuorescence for endodermal marker α-fetoprotein (AFP), ectodermal marker βIII-tubulin (TUBB3)
and mesodermal marker α-smooth muscle actin (SMA). Nuclei were stained with DAPI.
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a case of extreme tetralogy of Fallot (Cristo et al.,2017a). To better
understand the role of DAND5 in the human cardiac development
program, we have generated and characterized the NMSUNLi001-A
variant cell line, in which the c.455G > A DAND5 variant is hetero-
zygotic (Cristo et al.,2017b). This iPSC line was generated using Sendai-
virus reprogramming system, retained a stable karyotype, expressed
pluripotency markers (e.g., NANOG, OCT4, SOX2), and diﬀerentiated
towards the three germ layers in vitro (Cristo et al., 2017b).
Here, using CRISPR/Cas9-mediated genome editing, we were able
to generate an isogenic DAND5-corrected iPSC line, i.e., c.455 G
homozygous. The strategy for gene correction, in which we made use of
CRISPR-induced homology directed repair (HDR) technology using a
single-stranded oligonucleotide (ssODN) as a repair template, is illu-
strated in Fig 1A. DNA Sanger sequencing analysis of NMSUNLi003
conﬁrmed the correction of the heterozygotic c.455G > A DAND5 al-
teration (Fig 1B). The genetic identity of this isogenic cell line to the
parental NMSUNLi001-A variant cell line was conﬁrmed by STR ana-
lysis, showing that all 16 loci tested matched (Table 1). The DAND5-
corrected iPSC line showed a typical human embryonic stem cell (hESC)
colony-like morphology with a high nucleus/cytoplasm ratio (Fig 1C),
and was karyotypically normal (Fig 1D). Pluripotency was assessed by
immunoﬂuorescence for OCT4, NANOG, and SSEA4 pluripotency
markers (Fig 1E), and by the expression of endogenous pluripotency
factors OCT4, NANOG, KLF4, SOX2 (Fig 1F). In vitro embryoid body
(EB)-based diﬀerentiation, followed by immunoﬂuorescence analysis of
the endodermal marker α-fetoprotein (AFP), the mesodermal marker
smooth muscle actin (SMA) and the ectodermal marker βIII-tubulin
(TUBB3) revealed that the pluripotent isogenic DAND5-corrected iPSC
line diﬀerentiates into all three germ layers (Fig 1G). The presence of
mycoplasma was veriﬁed by PCR and the result was negative (Sup-
plementary Fig 1).
Thus, the generated corrected iUC-DAND5_455/10C cell line re-
presents the unmatched control to understand the contribution of the
c.455G > A DAND5 variant to the disease phenotype.
3. Materials and methods
3.1. iPSCs culture
Human iPSCs were cultured in StemFlex Medium (Thermo Fisher
Scientiﬁc) on hESC-Qualiﬁed Geltrex (Thermo Fisher Scientiﬁc) coated
plates at 37 °C in a humidiﬁed atmosphere (95% air, 5% CO2). Medium
was renewed daily and cells passaged using TrypLE Select (Thermo
Fisher Scientiﬁc) upon reaching 85% conﬂuence.
3.2. CRISPR gene correction
The heterozygous non-synonymous variant in exon 2 of DAND5
gene (c.455G > A) was corrected using CRISPR/Cas9-induced
homology directed repair technology. A speciﬁc sgRNA was designed
using the CRISPR design web tool in crispr.mit.edu, and was cloned into
pCAG-SpCas9-GFP-U6-gRNA plasmid (Addgene #79144). A total of
1.0 × 106 cells were co-nucleofected with 2 µg of the resulting plasmid,
and 1 µL of 100 µM ssODN using Neon transfection system (Thermo
Fisher Scientiﬁc), according to the manufacturer's instructions. After
transfection, the cells were cultured in StemFlex Medium (Thermo
Fisher Scientiﬁc) supplemented with RevitaCell Supplement at a 1X
ﬁnal concentration (Thermo Fisher Scientiﬁc), at 37 °C in a humidiﬁed
atmosphere (95% air, 5% CO2). 48 h post-nucleofection, cells were
FACS sorted and plated at single cell density into 96-well plates. Clones
were screened for the desired base correction by sequencing of ampli-
cons spanning the target site of DAND5 gene exon 2.
3.3. Fluorescent immunocytochemistry
Undiﬀerentiated or diﬀerentiated iUC-DAND5_455/10C cells were
ﬁxed in 4% paraformaldehyde, incubated with primary antibodies
overnight at 4 °C, listed in Table 2, and then incubated with Alexa Fluor
488-conjugated secondary antibodies overnight at 4 °C. Nuclei were
stained with DAPI at room temperature and cell images were acquired
with Zeiss Axio Imager Z2 microscope (Carl Zeiss) or Zeiss LSM710
confocal microscope.
3.4. In vitro diﬀerentiation potential by embryoid bodies formation assay
Embryoid bodies (EBs) consisting of 2000 cells/20 µL in E8 (Thermo
Fisher Scientiﬁc) medium plus polyvinyl alcohol (SIGMA) and
RevitaCell (Thermo Fisher Scientiﬁc) were generated using hanging
drop method. Two days after, EBs were suspended in 50% E8 medium
and 50% diﬀerentiation medium (DMEM with 20% FBS, Pen/Strep,
NEAA, 2 mM L-glutamine, and 0,1 mM β-mercaptoethanol) (Thermo
Fisher Scientiﬁc) and grown 3 more days on non-adherent Petri dishes
(LABBOX). At this time, the EBs were transferred onto Geltrex-coated
lummox 24-well plates (SARSTEDT) and cultured for another 14 days
or longer. Then, cells were ﬁxed with 4% formaldehyde and incubated
with the indicated primary antibodies speciﬁc for the three embryonic
germ layers.
3.5. Real-time PCR analysis
Real time PCR was carried out with SensiFAST SYBR Lo-ROX Mix
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography ESC-like morphology Fig. 1, panel C
Phenotype Qualitative analysis
(Immunocytochemistry)
Positive staining for expression of pluripotency markers: OCT4,
NANOG, SSEA4
Fig. 1 panel E
Quantitative analysis
(RT-qPCR)
Expression of pluripotency markers: NANOG, OCT4, KLF4, SOX2 Fig. 1 panel F
Genotype Karyotype (G-banding) and resolution 46XY,
Resolution 450–500
Fig. 1 panel D
Identity Microsatellite PCR (mPCR) OR STR
analysis]
N/A N/A
16 loci analyzed, match Supplementary Figure 2
Mutation analysis (If applicable) Sequencing Homozygous (corrected) Fig. 1 panel B
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by PCR. Negative Supplementary Figure 1
Diﬀerentiation potential Embryoid body formation Positive AFP endodermal staining, positive TUBB3 ectodermal
staining, positive SMA mesodermal staining
Fig. 1 panel G
Donor screening (Optional) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(Optional)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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(BIOLINE) and the primers listed in Table 2 on an ABI QuantStudio5
Real-Time PCR machine.
3.6. Karyotyping
Chromosome analysis was performed using GTG high resolution
banding technique at 400–500 band resolution, 30 metaphases ana-
lyzed (Service of GenoMed, Diagnósticos de Medicina Molecular, SA,
Lisboa, Portugal).
3.7. Mycoplasma contamination detection
The absence of mycoplasma was assessed by PCR using two pairs of
Primers listed in Table 2, and Mycoplasmacheck test (Barcode
84397997) by Euroﬁns Genomics (http://www.euroﬁnsgenomics.eu/).
3.8. STR analysis
Genomic DNA was extracted (Qiagen) from iUC-DAND_455/10C
cells (gDNA #10C) and the parental iUC-DAND_455/10 cells (gDNA
#7.39) and the cell line authentication (16 loci) was analyzed by STAB
VIDA (http://www.stabvida.com/).
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Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-OCT4
Mouse anti-SSEA4
Rabbit anti-NANOG
1:400
1:200
1:100
Abcam Cat# ab19857, RRID:AB_445175
Abcam Cat# ab16287, RRID:AB_778073
Abcam Cat# ab21624, RRID:AB_446437
Diﬀerentiation Markers Mouse anti-Human TUBB3
Mouse anti-Human SMA
Rabbit anti-Human AFP
1:400
1:600
1:200
Sigma-Aldrich Cat# T8660, RRID:AB_477590
Dako Cat# M0851, RRID:AB_2,223500
Dako Cat# A0008, RRID:AB_2,650473
Secondary antibodies Alexa Fluor 488-conjugated Donkey anti-Mouse IgG (H + L)
Alexa Fluor 488-conjugated Donkey anti-Rabbit IgG (H + L)
1:300
1:300
Jackson ImmunoResearch Labs Cat# 715-545-150, RRID:AB_2340846
Jackson ImmunoResearch Labs Cat# 711-545-152, RRID:AB_2313584
Primers
Target Forward/Reverse primer (5′−3′)
Pluripotency Markers (qPCR) NANOG
OCT3/4
SOX2
KLF4
CATGAGTGTGGATCCAGCTTG/CCTGAATAAGCAGATCCATGG
GACAGGGGGAGGGGAGGAGCTAGG/CTTCCCTCCAACCAGTTGCCCCAAAC
GGGAAATGGGAGGGGTGCAAAAGAGG/TTGCGTGAGTGTGGATGGGATTGGTG
ACCAGGCACTACCGTAAACACA/ GGTCCGACCTGGAAAATGCT
House-Keeping Genes (qPCR) GAPDH CTGGTAAAGTGGATATTGTTGCCAT/TGGAATCATATTGGAACATGTAAACC
Mycoplasma detection Pair 1
Pair 2
CTGCAGATTGCAAAGCAAGA/CCTCCTTCTTCACCTGCTTG
GGCGAATGGGTGAGTAACACG/CGGATAACGCTTGCGACCTATG
Targeted mutation analysis/sequencing DAND5 exon 2 GGAAGTGGACAGGTGATTATCC/CACGTCTTTCTTGGTCCATCTC
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